ERYTECH Pharma receives FDA IND clearance to initiate a clinical study in Acute Lymphoblastic Leukemia in the U.S.

  • Post author:
  • Post category:Newsroom

ERYTECH announced today that it has received clearance of its Investigational New Drug (IND) Application from the United States Food and Drug Administration (FDA) to initiate a Phase I clinical trial of its product ERYASP®, L-asparaginase loaded erythrocytes, in patients 40 years or older with newly diagnosed Acute Lymphoblastic Leukemia (ALL).